Maria Dobek Sells 1,462 Shares of Janux Therapeutics (NASDAQ:JANX) Stock

January 3, 2026 by InsiderTrades.com

Key Points

VP Maria Dobek sold 1,462 Janux shares on Jan. 2 at an average of $13.73 for ~$20,073, reducing her position by 8.68% to 15,373 shares (≈$211,071).
The Dobek sale is part of a broader round of insider selling the same day — including CEO David Campbell and several other executives — indicating notable insider liquidation activity.
Janux trades near its 52‑week low (~$13.65) with a market cap of ~$821M; analysts have a consensus "Moderate Buy" and $61.08 target, and the company recently beat quarterly EPS and revenue estimates (EPS -$0.39 vs -$0.60; revenue $10M vs $3.07M).

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) VP Maria Dobek sold 1,462 shares of the business's stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total value of $20,073.26. Following the transaction, the vice president owned 15,373 shares in the company, valued at approximately $211,071.29. This represents a 8.68% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Janux Therapeutics Stock Down 1.1%

NASDAQ JANX opened at $13.65 on Friday. Janux Therapeutics, Inc. has a fifty-two week low of $13.52 and a fifty-two week high of $61.59. The business has a 50 day moving average price of $22.51 and a two-hundred day moving average price of $23.74. The stock has a market cap of $821.05 million, a PE ratio of -8.13 and a beta of 2.88.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its earnings results on Thursday, November 6th. The company reported ($0.39) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million for the quarter, compared to analyst estimates of $3.07 million. Sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on JANX shares. UBS Group reaffirmed a "buy" rating and set a $57.00 target price on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Barclays lowered their price objective on Janux Therapeutics from $48.00 to $29.00 and set an "overweight" rating for the company in a research note on Wednesday, December 17th. Truist Financial started coverage on Janux Therapeutics in a research report on Wednesday, September 10th. They issued a "buy" rating and a $100.00 target price on the stock. Wall Street Zen raised shares of Janux Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, November 8th. Finally, Wolfe Research began coverage on shares of Janux Therapeutics in a research note on Tuesday, November 18th. They issued a "peer perform" rating for the company. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.08.

View Our Latest Report on JANX

Trending Headlines about Janux Therapeutics

Here are the key news stories impacting Janux Therapeutics this week:

Negative Sentiment: CEO David Alan Campbell sold 8,072 shares (~$110,829); he still holds 284,982 shares. Form 4 - Campbell
Negative Sentiment: Insider Thomas Diraimondo sold 2,505 shares (~$34,394); remaining position ~124,425 shares. Form 4 - Diraimondo
Negative Sentiment: Zachariah McIver sold 2,714 shares (~$37,263); post-sale holding ~23,286 shares. Form 4 - McIver
Negative Sentiment: VP Maria Dobek sold 1,462 shares (~$20,073); holds ~15,373 shares after the sale. Form 4 - Dobek
Negative Sentiment: Insider Charles M. Winter sold 2,401 shares (~$32,966); remaining holding ~77,721 shares. Form 4 - Winter

Hedge Funds Weigh In On Janux Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Squarepoint Ops LLC raised its stake in Janux Therapeutics by 230.0% during the second quarter. Squarepoint Ops LLC now owns 189,569 shares of the company's stock worth $4,379,000 after acquiring an additional 132,121 shares during the period. Quinn Opportunity Partners LLC grew its holdings in shares of Janux Therapeutics by 15.4% during the second quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company's stock valued at $1,384,000 after purchasing an additional 8,000 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Janux Therapeutics by 88.0% during the 1st quarter. Cubist Systematic Strategies LLC now owns 75,860 shares of the company's stock worth $2,048,000 after purchasing an additional 35,511 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Janux Therapeutics by 15.5% in the 2nd quarter. Geode Capital Management LLC now owns 902,312 shares of the company's stock worth $20,845,000 after purchasing an additional 121,403 shares during the last quarter. Finally, AlphaQuest LLC boosted its position in Janux Therapeutics by 3,658.9% during the 2nd quarter. AlphaQuest LLC now owns 9,698 shares of the company's stock valued at $224,000 after purchasing an additional 9,440 shares during the period. 75.39% of the stock is currently owned by institutional investors.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.